1. Home
  2. SYBX vs DEVS Comparison

SYBX vs DEVS Comparison

Compare SYBX & DEVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYBX
  • DEVS
  • Stock Information
  • Founded
  • SYBX N/A
  • DEVS N/A
  • Country
  • SYBX United States
  • DEVS Canada
  • Employees
  • SYBX N/A
  • DEVS N/A
  • Industry
  • SYBX Biotechnology: Pharmaceutical Preparations
  • DEVS
  • Sector
  • SYBX Health Care
  • DEVS
  • Exchange
  • SYBX Nasdaq
  • DEVS NYSE
  • Market Cap
  • SYBX 16.5M
  • DEVS 16.5M
  • IPO Year
  • SYBX N/A
  • DEVS N/A
  • Fundamental
  • Price
  • SYBX $1.36
  • DEVS $0.43
  • Analyst Decision
  • SYBX Hold
  • DEVS
  • Analyst Count
  • SYBX 1
  • DEVS 0
  • Target Price
  • SYBX N/A
  • DEVS N/A
  • AVG Volume (30 Days)
  • SYBX 19.0K
  • DEVS 224.7K
  • Earning Date
  • SYBX 03-18-2025
  • DEVS 03-04-2025
  • Dividend Yield
  • SYBX N/A
  • DEVS N/A
  • EPS Growth
  • SYBX N/A
  • DEVS N/A
  • EPS
  • SYBX N/A
  • DEVS N/A
  • Revenue
  • SYBX $2,777,000.00
  • DEVS N/A
  • Revenue This Year
  • SYBX N/A
  • DEVS N/A
  • Revenue Next Year
  • SYBX N/A
  • DEVS N/A
  • P/E Ratio
  • SYBX N/A
  • DEVS N/A
  • Revenue Growth
  • SYBX 292.23
  • DEVS N/A
  • 52 Week Low
  • SYBX $1.22
  • DEVS $0.41
  • 52 Week High
  • SYBX $2.04
  • DEVS $1.91
  • Technical
  • Relative Strength Index (RSI)
  • SYBX 45.23
  • DEVS N/A
  • Support Level
  • SYBX $1.31
  • DEVS N/A
  • Resistance Level
  • SYBX $1.40
  • DEVS N/A
  • Average True Range (ATR)
  • SYBX 0.07
  • DEVS 0.00
  • MACD
  • SYBX 0.00
  • DEVS 0.00
  • Stochastic Oscillator
  • SYBX 60.61
  • DEVS 0.00

About SYBX Synlogic Inc.

Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.

About DEVS DEVVSTREAM CORP

DevvStream Corp is a technology based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.

Share on Social Networks: